Skip to content
Screener

Alto Neuroscience ANRO Q1 2026 earnings

Reported May 13, 2026 · Before market open

EPS-$0.80Miss by $0.24
EPS estimate-$0.56

Next report

Nov 11, 2026 (in 2 months)
EPS estimate-$0.67

Financials

Q1 2026

Income statement

See full
Operating income-$27.1M-73.1%
Net income-$26.2M-73.0%
EPS (diluted)-$0.80-42.9%

Balance sheet

See full
Cash & equivalents$264.3M+63.9%
Total debt$20.9M-17.2%
Total equity$243.4M+75.0%
Total assets$276.3M+60.7%

Cash flow

See full
Operating cash flow-$27.1M-63.6%
CapEx$556.0K+2,217%
Free cash flow-$27.6M-66.7%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$718.14M+1,128%
Enterprise value$474.75M+712%

Returns & leverage

See full
Return on equity-38.9%+0.9pp
Debt / equity0.1×-0.1×
Current ratio20.5×-2.0×

FAQ

When did Alto Neuroscience report Q1 2026 earnings?
Alto Neuroscience (ANRO) reported Q1 2026 earnings on May 13, 2026 before market open.
What were Alto Neuroscience's Q1 2026 revenue and EPS?
Alto Neuroscience reported eps of $-0.80 for Q1 2026.
Did Alto Neuroscience beat estimates in Q1 2026?
EPS missed the consensus estimate of $-0.56 by $0.24.
How did Alto Neuroscience's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, eps declined 50.9% from $-0.53.
Where can I find Alto Neuroscience's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001999480-26-000011) and the 10-Q periodic report (0001999480-26-000012) directly on SEC EDGAR. The filing index links above go to sec.gov.